“Real-World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States

Catheterization and Cardiovascular Interventions

Volumn 88, Issue 4, 2016, Pages 535-544

  Larmore, Cynthia ^a   Effron, Mark B ^a   Molife, Cliff ^a   DeKoven, Mitch ^b   Zhu, Yajun ^a   Lu, Jingsong ^b   Karkare, Swapna ^b   Lieu, Hsiao D ^a   Lee, Won Chan ^b   Vetrovec, George W ^c  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

antiplatelet; major bleeding; myocardial infarction; observational study

Indexed keywords

PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES; ADVERSE EFFECTS; AGE; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; FACTUAL DATABASE; HOSPITALIZATION; MIDDLE AGED; ODDS RATIO; RISK FACTOR; TIME FACTOR; TRENDS;

ACUTE CORONARY SYNDROME; ADENOSINE; AGE FACTORS; AGED; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRACTICE PATTERNS, PHYSICIANS'; PRASUGREL HYDROCHLORIDE; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84991671984     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26279     Document Type: Article

References (24)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D Turner MB, American Heart Association Statistics Committee Stroke Statistics Subcommittee. Heart disease and stroke statistics—2014 update: A report from the American Heart Association. Circulation 2015;131:e29–e322.
2. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Diebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:e344–e426.
3. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362–e425.
4. Steg G, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D, Committee for Practice Guidelines ESC. (CPG) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569–2619.
5. Hamm CW, Bassand JP, Agewall S, Fax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force on the management of acute coronary syndromes (ACS) in patients presenting without ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054.
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM TRITON-TIMI 3 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF Harrington RA, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
8. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romangnoli E, Sangiorgi G, Angiolillo DJ, Valgimigli M, Testa L, Gaita F, Sheiban I. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011;150:325–331.
9. Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis 2013;36:223–232.
10. Steiner S, Moertl D, Chen L, Coyle D, Wells GA. Network meta-analysis of prasugrel, ticagrelor, high-and standard dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost 2012;108:318–327.
11. ® [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc./Indianapolis, IN: Eli Lilly and Company; November, 2013. Available at: http://pi.lilly.com/us/effient.pdf. Accessed on 15 October 2015.
12. Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Branwald E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011;108:905–911.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
14. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516–524.
15. Rubin DB. The design versus the analysis of observational studies for causal effects: Parallels with the design of randomized trials. Stat Med 2007;26:20–36.
16. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291–303.
17. ® [package insert]. Wilmington, DE: AstraZeneca; December, 2013. Available at: http://www.azpicentral.com/brilinta/brilinta.pdf#page=1. Accessed on 15 October 2015.
18. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DM, Stone GW, Curzen N, Geisler T, ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, for the Working Group on On-Treatment Platelet Reactivity. J Am Coll Cardiol 2013;62:2261–2273.
19. Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS, Rohatagi S, Farid NA, Jakubowski JA, Winters KJ. Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects. Platelets 2009;20:316–327.
20. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–1856.
21. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO PLATELET substudy. J Am Coll Cardiol 2010;56:1456–1462.
22. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Demelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention. J Am Coll Cardiol 2012;60:193–199.
23. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011;124:544–554.
24. Kohli P, Udel JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes related with prasugrel versus clopidogrel. J Am Coll Cardiol 2014;63:225–232.